French Medical Device Firm Pays $1.2M in US Foreign Bribery Probe; Executives Indicted
Balt SAS, a medical device company headquartered in France, has resolved a bribery investigation led by the U.S. Department of Justice involving illegal payments to a top physician at a state-owned French hospital. Under the Foreign Corrupt Practices Act (FCPA), Balt voluntarily disclosed the misconduct, cooperated with investigators, and agreed to pay $1.2 million in disgorgement, avoiding prosecution.
The scheme reportedly spanned several years, with bribes aimed at securing business advantages for the company in the French healthcare sector. Two individuals—a healthcare executive and a sales consultant—have been indicted in connection with the case, underscoring prosecution efforts targeting those responsible for corrupt practices.
This case sends a strong signal to multinational companies about the risks of corrupt dealings in government healthcare procurement globally. It also illustrates cooperation between U.S. and French authorities, as France’s Parquet National Financier coordinated with the DOJ on the investigation. The outcomes could lead to increased scrutiny and compliance demands for medical device companies operating internationally.
Hospitals funded by public monies, healthcare professionals, and patients stand to benefit from tighter controls and transparency around supplier relationships, potentially reducing corruption and improving healthcare outcomes.
